About this Research Topic
Antibodies have been used for more than 100 years for infections, and the first use of antibodies (intravenous immunoglobulin) as a replacement therapy for X-linked agammaglobulinemia, was almost 70 years ago. Currently, there are more than 423 primary immunodeficiencies and more than 400 different gene mutations. Furthermore, investigations have focused on understanding the molecular and cellular pathways of intravenous immunoglobulin (IVIG) effects on various components of the immune system. This has led to the ever-expanding use of IVIG as an anti-inflammatory and immunomodulatory agent in a variety of inflammatory and autoimmune diseases. In addition, progress has been made in understanding the interactions of IgG with various FcRs, and the effect of modulation of IgGFc receptor on immunomodulatory activity of IVIG, and its role in autoimmune disorders and protection against viral infections. This is of particular importance since certain autoimmunity and autoimmune diseases are frequently present in certain primary immunodeficiency diseases (PIDs). Novel approaches have been developed to produce large quantities of highly potent and/or broadly cross-reactive human monoclonal antibodies (super-antibodies') for intervention against infections. A molecular understanding of a number of primary immunodeficiency disease has allowed the development of targeted monoclonal antibodies therapy in a number of PIDs and associated complications. Further, monoclonal antibodies directed against stem cells to create bone marrow niches for hematopoietic stem cell transplantation (HSCT) are currently being investigated.
In this Research Topic on “Advances in Antibody Therapy in Primary Immunodeficiency”, we welcome the submission of Original Research and Review articles related to the following topics, especially novel approaches to develop/engineer monoclonal antibodies or modifications in IVIG for the treatment of PIDs, and mechanisms of actions of IVIG to present the State-of-the-Art of Antibody therapy in primary Immunodeficiency Diseases.
1. Passive Immunity: A historical perspective
2. Changes in antibody molecules during germinal center reaction: Implications in vaccine development
3. “Super-antibodies”-New generation of monoclonal antibodies
4. FcRs: Role in inflammation and therapeutic targets
5. Role of FcR in therapeutic effects of intravenous Immunoglobulin in inflammatory and autoimmune diseases
6. Targeted antibody therapy for autoimmune and immune dysregulation associated with primary immunodeficiencies
7. Antibodies in Covid-19 and PID: Mechanism and therapeutics
8. Monoclonal antibodies therapy in autoinflammatory diseases
9. Monoclonal antibodies against HSC for HSCT in PID
10. Cytokine targeted therapy in primary immunodeficiency diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.